UK-MHRA inspects Indoco’s solid dosages facility in Goa

Indoco Remedies announced that the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) inspected its solid dosages manufacturing facility in Goa (Plant I) from September 7 to September 9, 2026.

The UK-MHRA current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations. 

Commenting on the development, Aditi Panandikar, Managing Director – Indoco Remedies said, “This plant has been consistently catering to the regulated markets of UK, Europe, South Africa, New Zealand, Australia and Canada for several years and is expected to contribute to approx. 30 per cent of total international business. The successful completion of the UKMHRA cGMP inspection with no critical or major observations is a strong validation of our robust quality systems. This further testifies our unwavering commitment to Good Manufacturing Practices and world class quality standards. The accolade not only reinforces the trust our global partners place in us, but strengthens our ability to serve patients worldwide.” 

The facility which manufactures solid dosages and liquid dosages is approved by USFDA, (solid dosages, creams and capsules), TGA-Australia (solid dosages, liquid orals, creams and ointments) and by EU Malta, i.e., MMA – Malta Medicine Authority (solid dosages). The Plant also holds WHO-GMP approval and has successfully faced an audit by SAHPRA (for solid dosages).

The post UK-MHRA inspects Indoco’s solid dosages facility in Goa appeared first on Express Pharma.